Contribute Try STAT+ Today

In a closely watched decision, the New Jersey Supreme Court ruled that higher federal standards of evidence should be applied in product liability litigation, giving a boost to drug makers because so many lawsuits are filed in the state by people who claim they were harmed by medicines.

The ruling came in a long-running case involving a Roche (RHHBY) acne drug that was blamed for causing Crohn’s disease in more than 2,100 lawsuits filed against the drug maker. At issue were scientific studies the company sought to use to defeat the lawsuits, which prompted competing arguments over differing standards for assessing the validity of the studies and, in particular, expert testimony.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.